Hospira Issues a Voluntary Global Recall of Multiple Lots of Ketorolac Tromethamine Injection Due to Potential Particulate in Glass Vials

Hospira, Inc., (NYSE: HSP) has announced a voluntary recall of ketorolac tromethamine injection, USP in the United States and Singapore due to potential particulate. The presence of particulate has been confirmed through a customer report of visible, floating particulate identified in glass fliptop vials.

Product Images
Click a thumbnail to see full size image (FDA image source)
  • Hospira Issues a Voluntary Global Recall of Multiple Lots of Ketorolac Tromethamine Injection Due to Potential Particulate in Glass Vials
  • Hospira Issues a Voluntary Global Recall of Multiple Lots of Ketorolac Tromethamine Injection Due to Potential Particulate in Glass Vials
  • Hospira Issues a Voluntary Global Recall of Multiple Lots of Ketorolac Tromethamine Injection Due to Potential Particulate in Glass Vials
  • Hospira Issues a Voluntary Global Recall of Multiple Lots of Ketorolac Tromethamine Injection Due to Potential Particulate in Glass Vials
  • Hospira Issues a Voluntary Global Recall of Multiple Lots of Ketorolac Tromethamine Injection Due to Potential Particulate in Glass Vials
  • Hospira Issues a Voluntary Global Recall of Multiple Lots of Ketorolac Tromethamine Injection Due to Potential Particulate in Glass Vials
  • Hospira Issues a Voluntary Global Recall of Multiple Lots of Ketorolac Tromethamine Injection Due to Potential Particulate in Glass Vials
  • Hospira Issues a Voluntary Global Recall of Multiple Lots of Ketorolac Tromethamine Injection Due to Potential Particulate in Glass Vials
 
 
comments powered by Disqus